Protease Inhibitors: all 1,856 studies that test it

Page 4 of 19. Open to participants first (69), then studies with results posted, then the rest; newest registration first within each.

• Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/HCV Seronegative VolunteersCompletedNCT02404805Not applicableResults posted
• Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal ImpairmentCompletedNCT02402452Phase 1Results posted
• Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's MacroglobulinemiaCompletedNCT02400437Phase 2Results posted
• Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Co-Administered With Sofosbuvir With and Without Ribavirin in Treatment-Naive HCV Genotype 1-Infected AdultsCompletedNCT02399345Phase 3Results posted
• Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic ImpairmentCompletedNCT02397707Phase 1Results posted
• Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell TransplantCompletedNCT02389517Phase 2Results posted
• Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced AdultsTerminatedNCT02386098Phase 2Results posted
• Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV InfectionCompletedNCT02378961Phase 2Results posted
• Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV InfectionCompletedNCT02378935Phase 2Results posted
• Drug-Drug Interaction Study Between TAK-272 and Itraconazole, Digoxin or MidazolamCompletedNCT02370615Phase 1Results posted
• Phase I Open-label Study to Evaluate Pharmacokinetics of TAK-272 in Participants With Renal or Hepatic ImpairmentCompletedNCT02367872Phase 1Results posted
• A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus InfectionCompletedNCT02356562Phase 2Results posted
• Tosedostat With Capecitabine in Patients With Metastatic Pancreatic AdenocarcinomaTerminatedNCT02352831Phase 1/2Results posted
• Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 InfectionCompletedNCT02349048Phase 2Results posted
• Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C InfectionCompletedNCT02340962Phase 2Results posted
• Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin LymphomaActive, not recruitingNCT02339922Phase 2Results posted
• A Phase 2 Dose-finding Study of TAK-272 in Participants With Type 2 Diabetes Mellitus and MicroalbuminuriaCompletedNCT02332824Phase 2Results posted
• Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)CompletedNCT02332707Phase 2Results posted
• Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated CirrhosisCompletedNCT02319031Phase 3Results posted
• A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)CompletedNCT02312258Phase 3Results posted
• Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 CirrhoticsCompletedNCT02304159Phase 4Results posted
• Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) in RemissionTerminatedNCT02302846Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus InfectionCompletedNCT02292719Phase 2Results posted
• A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin DeficiencyCompletedNCT02282527Phase 2/3Results posted
• A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected ParticipantsCompletedNCT02268864Phase 2Results posted
• A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)CompletedNCT02265237Phase 3Results posted
• An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver DiseaseCompletedNCT02262728Phase 2Results posted
• Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple MyelomaActive, not recruitingNCT02253316Phase 2Results posted
• Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065)CompletedNCT02252016Phase 3Results posted
• Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Naïve Hepatitis C Virus Participants (MK-5172-067)CompletedNCT02251990Phase 3Results posted
• Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus InfectionCompletedNCT02250807Phase 3Results posted
• MLN9708 for the Prophylaxis of Chronic Graft-versus-host Disease in Patient Undergoing Allogeneic TransplantationCompletedNCT02250300Phase 1/2Results posted
• A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 InhibitorCompletedNCT02247739Phase 2Results posted
• Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected AdultsCompletedNCT02246998Phase 4Results posted
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 InfectionCompletedNCT02243293Phase 2/3Results posted
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 InfectionCompletedNCT02243280Phase 2Results posted
• Drug-Drug Interaction Study: ASP2151 and RitonavirCompletedNCT02223351Phase 1Results posted
• A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and CirrhosisCompletedNCT02219503Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated CirrhosisCompletedNCT02219477Phase 3Results posted
• A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adults With Genotype 1b (GT1b) InfectionCompletedNCT02216422Phase 3Results posted
• Phase II Trial of Nelfinavir With Concurrent Chemoradiotherapy in Squamous Cell Carcinoma of the Head and NeckCompletedNCT02207439Phase 2Results posted
• Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney DiseaseCompletedNCT02207088Phase 3Results posted
• Study of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Japanese Participants With Chronic Hepatitis C (MK-5172-058)CompletedNCT02203149Phase 2/3Results posted
• Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV InfectionCompletedNCT02202980Phase 2Results posted
• Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral TherapyTerminatedNCT02194998Phase 2Results posted
• Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus InfectionCompletedNCT02185794Phase 1Results posted
• A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell TransplantCompletedNCT02181413Phase 3Results posted
• Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN)TerminatedNCT02176486Phase 1Results posted
• Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)CompletedNCT02175966Phase 2Results posted
• A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1CompletedNCT02170727Phase 3Results posted
• Nonmyeloablative Haploidentical Transplant Followed by MLN9708CompletedNCT02169791Phase 2Results posted
• The SIM-SOF Trial for Hepatitis CCompletedNCT02168361Phase 4Results posted
• Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple MyelomaCompletedNCT02168101Phase 2Results posted
• Study Assessing the Effects of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy ParticipantsCompletedNCT02159352Phase 1Results posted
• Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell LymphomasCompletedNCT02158975Phase 2Results posted
• Efficacy and Safety Study of Darunavir for the Treatment of HIV/AIDSCompletedNCT02155101Phase 3Results posted
• ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCLCompletedNCT02141451Phase 1/2Results posted
• Efficacy and Safety of Grazoprevir (MK-5172), Elbasvir (MK-8742), and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074)CompletedNCT02133131Phase 2Results posted
• Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCVCompletedNCT02124044Phase 2Results posted
• Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple MyelomaCompletedNCT02119468Phase 1/2Results posted
• Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059)CompletedNCT02115321Phase 2/3Results posted
• Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without CirrhosisCompletedNCT02114177Phase 3Results posted
• Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and CirrhosisCompletedNCT02114151Phase 3Results posted
• Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)CompletedNCT02105701Phase 3Results posted
• An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus (HCV) Genotype (GT)1, 4, or 6 Infection in Treatment-Naïve Participants Who Are on Opiate Substitution Therapy (MK-5172-062)CompletedNCT02105688Phase 3Results posted
• An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus in Participants Who Are Co-Infected With Human Immunodeficiency Virus:C-EDGE CO-INFXN (MK-5172-061)CompletedNCT02105662Phase 3Results posted
• Study of Efficacy and Safety of Grazoprevir (MK-5172)/Elbasvir (MK-8742) Combination Regimen for Treatment-Naïve Participants With Chronic Hepatitis C Virus Genotypes 1, 4, and 6 (MK-5172-060)CompletedNCT02105467Phase 3Results posted
• Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin in Participants With Chronic Hepatitis C Who Failed Prior Direct-Acting Antiviral Therapy (MK-5172-048)CompletedNCT02105454Phase 2Results posted
• Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes MellitusTerminatedNCT02093221Phase 2Results posted
• Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052)CompletedNCT02092350Phase 2/3Results posted
• Safety, Pharmacokinetics, and Pharmacodynamics of Ruzasvir (MK-8408) in Participants With Hepatitis C Infection (MK-8408-003)CompletedNCT02076100Phase 1Results posted
• A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) InfectionCompletedNCT02068222Phase 2Results posted
• Nelfinavir in Systemic Lupus ErythematosusTerminatedNCT02066311Phase 2Results posted
• MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple MyelomaCompletedNCT02057640Phase 1/2Results posted
• Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple MyelomaCompletedNCT02046070Phase 2Results posted
• Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCVCompletedNCT02032901Phase 3Results posted
• A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.CompletedNCT02032888Phase 3Results posted
• Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver TransplantCompletedNCT02032875Phase 3Results posted
• Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT02030405Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) InfectionCompletedNCT02023112Phase 3Results posted
• Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) InfectionCompletedNCT02023099Phase 3Results posted
• Investigation of Potential Drug-drug Interactions Between Faldaprevir and the Immunosuppressant Drugs Cyclosporine or TacrolimusCompletedNCT02016625Phase 1Results posted
• Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude DualCompletedNCT01995266Phase 3Results posted
• A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)CompletedNCT01995071Phase 2Results posted
• Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Genotype 1CompletedNCT01994486Phase 2Results posted
• Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive AdultsCompletedNCT01968551Phase 3Results posted
• Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced AdultsCompletedNCT01967940Phase 3Results posted
• Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic CancerCompletedNCT01959672Phase 2Results posted
• Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIBCompletedNCT01953783Phase 1Results posted
• Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refractory Follicular LymphomaCompletedNCT01939899Phase 2Results posted
• A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver TransplantationCompletedNCT01938625Phase 2Results posted
• The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050)CompletedNCT01937975Phase 1Results posted
• Alpha-1 Anti-Trypsin (AAT) Treatment in Acute Myocardial InfarctionCompletedNCT01936896Phase 1/2Results posted
• Efficacy and Safety of Combination Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)CompletedNCT01932762Phase 2Results posted
• Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver DysfunctionCompletedNCT01912222Phase 1Results posted
• Open Label Single Dose Phase I Trial of BI 201335 to Study Pharmacokinetics and Safety in Patients With Compensated Liver CirrhosisCompletedNCT01909778Phase 1Results posted
• Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ARTCompletedNCT01903031Phase 2Results posted
• Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute LeukemiaTerminatedNCT01887587Phase 1Results posted
• Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIVTerminatedNCT01866930Phase 3Results posted
• Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain AmyloidosisCompletedNCT01864018Phase 1/2Results posted

← Protease Inhibitors overview